CTOs on the Move

JeNu Biosciences

www.jenu.com

 
JeNu Biosciences was founded by a leading Washington bio scientist and a medical technology entrepreneur. While working on an ultrasound device for topical drug delivery, they became curious about using ultrasound to improve cosmetic skin care product delivery. High energy ultrasound has been proven effective at pushing drugs through the skin, but in the process cells are damaged and high heat causes intense pain. But since cosmetics only need to be absorbed into the top layer of skin rather than through the skin like drugs they thought a low energy ultrasound device might work. After many attempts they proved that ...
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.jenu.com
  • 1101 N Northlake Way Ste 200
    Seattle, WA USA 98103
  • Phone: 866.565.5368

Executives

Name Title Contact Details

Similar Companies

Sanarus Medical

Sanarus Medical is a Pleasanton, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

HCI Hospital TV

HCI Hospital TV is a Loveland, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

zuChem

zuChem is a leading producer of unique sugars for human health and nutrition. zuChem develops proprietary technologies for the manufacture of glycochemicals and carbohydrates for use in the food, specialty and fine chemical markets. The zuChem approach is unique, combining new proprietary technologies with the more traditional synthetic techniques. zuChem researchers have a proven track record in developing and implementing scalable, industrial quality processes.

Ashwood Retirement and Assisted

Ashwood Retirement and Assisted is a Austin, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cellenkos Incorporated

Cellenkos is an early stage clinical biotechnology company that focuses on cord blood-derived T-regulatory cellular therapies for the treatment of autoimmune diseases and inflammatory conditions. Cellenkos is founded on the technologies arising from the laboratory investigations of Simrit Parmar, M.D. Cellenkos` lead product CK0801 delivers clinically meaningful doses of allogeneic cord blood T-regulatory cells to overcome immune dysfunction.